GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

ligufalimab   Click here for help

GtoPdb Ligand ID: 13887

Synonyms: AK-117 | AK117
Immunopharmacology Ligand
Compound class: Antibody
Comment: Ligufalimab (AK117) is a humanized IgG4 anti-CD47 antibody [1-2]. In the tumour microenvironment blocking CD47 interaction with its receptor SIRPα enhances M2 macrophage-mediated phagocytosis of CD47-expressing malignant cells from variety of tumour types. Unlike other anti-CD47 antibodies (such as magrolimab) ligufalimab does not induce hemagglutination, so should be devoid of hematotoxic side effects (anemia and thrombocytopenia) due to the expression of CD47 on erythrocytes.
Click here for help
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
Interleukin-4 receptor subunit α Hs Antibody Binding - - - 2
[2]
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
CD47 Hs Antibody Binding 9.8 pKd - 2
pKd 9.8 (Kd 1.52x10-10 M) [2]
Description: Binding affinity determined by SPR
CD47 Hs Antibody Binding 9.4 – 9.5 pEC50 - 2
pEC50 9.5 (EC50 3.2x10-10 M) [2]
Description: Binding to CD47 on Raji cells
pEC50 9.4 (EC50 4x10-10 M) [2]
Description: Binding to CD47 on Jurkat cells